Sindrom Metabolik pada Pasien Kanker di Yogyakarta, Indonesia
DOI:
https://doi.org/10.30595/pharmacy.v17i1.5729Keywords:
jenis stage, kanker, lama terapi, sindrom metabolikAbstract
Provinsi DI Yogyakarta memiliki prevalensi kanker tertinggi di Indonesia. Di sisi lain, pasien kanker mungkin memiliki risiko penyakit kardiovaskular akibat kemoterapi yang diterima. Penelitian ini bertujuan untuk mengobservasi sindrom metabolik pada pasien kanker di Yayasan Kanker Indonesia di Yogyakarta, sehingga dapat digunakan sebagai skrining awal dan langkah preventif mengurangi risiko penyakit kardiovaskuler maupun relapsing kanker. Jenis penelitian ini adalah observasional analitik dengan desain potong lintang (cross-sectional) dengan mengikutsertakan responden di Yayasan Kanker Indonesia selama bulan Agustus 2018. Kriteria inklusi subyek penelitian adalah pasien terdiagnosa kanker, berusia 20-74 tahun, dan bersedia ikut serta dalam penelitian dengan menandatangani informed consent. Analisis komparatif kategorik digunakan untuk melihat pengaruh jenis diagnosa kanker, stage, dan lama terapi terhadap sindrom metabolik dengan menggunakan Chi-Square. Kanker nasofaring merupakan kanker yang paling banyak ditemui dengan 36,9% pasien pada stage 3 dan 4, serta 55% pasien telah menjalani terapi >3 bulan. Jumlah pasien dengan gula darah sewaktu (GDS)>200 mg/dL, status obesitas [berdasarkan Body Mass Index (BMI) dan lingkar pinggang (LP)], dan hipertensi masing-masing sebesar 6,3; 50,5; dan 47,7%. Terdapat perbedaan proporsi BMI yang bermakna secara statistik (p=0,03) terhadap jenis kanker, namun tidak ditemukan pada variabel yang lain. Untuk bisa mengambil kesimpulan yang lebih baik, perlu adanya peninjuan lebih dalam ke pihak rumah sakit melalui rekam medis terkait dengan stage dan terapi yang diterima oleh pasien.
References
Adham, M., Kurniawan, A.N., Muhtadi, A.I., Roezin, A., Hermani, B., Gondhowiardjo, S., Tan, I.B., Middeldorp, J.M. 2012. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chinese Journal of Cancer, 31:185–196.
American Cancer Society. 2019. Cancer Facts&Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Data diakses pada 15 Oktober 2019.
Barberio, A.M., Alareeki, A., Viner, B., Pader, J., Vena, J.E., Arora, P., Friedenreich, C.M., Brenner, D.R. 2019. Central body fatness is a stronger predictor of cancer risk than overall body size. Nature Communications, 10:383.
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D.A., Smeeth, L. 2014. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet (London, England), 384:755–765.
Bicakli, D.H., Varol, U., Degirmenci, M., Tunali, D., Cakar, B., Durusoy, R., Karaca, B., Sanli, U.A., Uslu, R. 2016. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy, 22 (1): 46-53.
Braun, S., Bitton-worms, K., Leroith, D. 2011. The link between the metabolic syndrome and cancer. International Journal of Biological Sciences, 7(7):1003-1015.
Chan, H., Ismail, S. 2014. Side effects of chemotherapy among cancer patients in a malaysian general hospital : experiences , perceptions and informational needs from clinical pharmacists. Asian Pacific Journal of Cancer Prevention, 15(13):5305–5309.
Crawley, D.J., Holmberg, L., Melvin, J.C., Loda, M., Chowdhury, S., Rudman, S.M., Van Hemelrijck, M. 2014. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer, 14: 985.
Daher, I.N., Daigle, T.R., Bhatia, N., Durand, J. 2012. The prevention of cardiovascular disease in cancer survivors. Texas Heart Institute Journal, 39(2):190–198.
Duan, W., Shen, X., Lei, J., Xu, Q., Yu, Y., Li, R., Wu, E., Ma, Q. 2014. Hyperglycemia, a neglected factor during cancer progression. Biomed Research International, 2014: 461917.
Greenlee, H., Unger, J.M., LeBlanc, M., Ramsey, S., Hershman, D.L., 2017. Association between body mass index (BMI) and cancer survival in apooled analysis of 22 clinical trials. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology, 26(1): 21-29.
Haas, E.C. De, Altena, R., Boezen, H.M., Zwart, N., Smit, A.J., Bakker, S.J.L., Roon, A.M. Van, Postma, A., Wolffenbuttel, B.H.R., Hoekstra, H.J., Leeuwen, F.E. Van, Sleijfer, D.T., Gietema, J.A. 2018. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 24(3):749-755.
Kassi, E., Pervanidou, P., Kaltsas, Chrousos, G., 2011. Metabolic syndrome: definition and controversies. BMC Medicine. 9:48.
Kementerian Kesehatan Republik Indonesia. 2019. URL http://www.depkes.go.id/article/view/19020100003/hari-kanker-sedunia-2019.html. Data diakses pada 15 Oktober 2019.
Kementerian Kesehatan RI. 2013. Riset Kesehatan Dasar. Jakarta: Kementerian Kesehatan RI.
Koene, R.J., Prizment, A.E., Blaes, A., Konety, S.H. 2017. HHS Public Access 133: 1104–1114. doi:10.1161/CIRCULATIONAHA.115.020406.Shared
Lagergren, P., Schandi, A., Aaronson, N.K., Adami, H., de Lorenzo, F., Denis, L., Faithfull, S., Liu, L., Meunier, F., Ulrich, C. 2019. Cancer survivorship: an integral part of Europe's research agenda. Molecular Oncology, 13(3):624-635.
Lavalette, C., Trétarre, B., Rebillard, X., Lamy, P.-J., Cénée, S., Menegaux, F. 2018. Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. Oncotarget, 9: 34485–34494.
Lee, K.R., Seo, M.H., Do Han, K., Jung, J., Hwang, I.C. 2018. Waist circumference and risk of 23 site-specific cancers: a population-based cohort study of Korean adults. British Journal of Cancer 119:1018–1027.
Pearce, A., Haas, M., Viney, R., Pearson, S., Haywood, P., Brown, C., Ward, R. 2017. Incidence and severity of self-reported chemotherapy side effects in routine care : A prospective cohort study. PlosOne, 1–12.
Rossi, S., Baili, P., Capocacia, R., Lorez, M., De Angelis, R. 2015. The eurocare-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods. European Journal of Cancer, 51(15):2104-2119.
Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D.S., Ntzani, E.E., Tsilidis, K.K. 2019. Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies. Scientific Reports, 9:8565.
Souza, V.B. de, Silva, E.N., Ribeiro, M.L., Martins, W. de A. 2015. Hypertension in patients with cancer. Arquivos Brasileiros de Cardiologia, 104:246–252.
Shachar, S.S., Williams, G.R. 2017. The obesity paradox in cancer-moving beyond BMI. Cancer Epidemiology, Biomarkers & Prevention, 26:13–16.
Uzunlulu, M., Telci, O., Aytekin, C. 2016. Association between metabolic syndrome and cancer. Annals of Nutrition & Metabolism, 68:173–179.
Vulcan, A., Manjer, J., Ohlsson, B. 2017. High blood glucose levels are associated with higher risk of colon cancer in men: a cohort study. BMC Cancer, 17:842.
Wang, G., Su, C., Yin, T.A.O. 2017. Paclitaxel and platinum‑based chemotherapy results in transient dyslipidemia in cancer patients. Molecular and Clinical. Oncology, 6:261–265.
Westerink, M.D.N.L., Nuver, J.M.D., Lefrandt, J.D.M.D., Vrieling, A.H.M.D., Gietema, J.A.M.D., Walenkamp, A.M.E.M.D. 2016. Critical reviews in oncology/ hematology cancer treatment induced metabolic syndrome : improving outcome with lifestyle. Critical Reviews in Oncology/Hematology, 108:128–136.
Willemse, P.M., Burggraaf, J., Hamdy, N.A.T., Weijl, N.I., Vossen, C.Y., Wulften, L. Van. 2013. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. British Journal of Cancer, 109:60–67.
World Health Organization. 2017. Global Health Observatory (GHO) data. https://www.who.int/gho/ncd/mortality_morbidity/en/. Data diakses pada 15 Oktober 2019.
Wu, L., Li, C., Pan, L. 2018. Nasopharyngeal carcinoma: A review of current updates. Experimental and Therapeutic Medicine, 15:3687–3692.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
